What is CJC-1295 No DAC?
CJC-1295 No DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH), specifically based on the GHRH 1-29 fragment. The modification involves four amino acid substitutions — replacing Ala2 with D-Ala, Gln8 with Ala, Ala15 with Ala (GABA), and Leu27 with norvaline — which collectively confer enhanced resistance to dipeptidyl peptidase IV (DPP-IV) enzymatic degradation compared to native GHRH.
The "No DAC" designation distinguishes this variant from CJC-1295 with DAC (Drug Affinity Complex), which incorporates a maleimidoproprionic acid (MPA) modification enabling covalent albumin binding. The No DAC form retains a half-life of approximately 30 minutes in plasma, producing characteristically pulsatile GH release patterns that more closely replicate the endogenous hypothalamic GHRH signalling rhythm observed in pituitary physiology research.
ClaraScience supplies CJC-1295 No DAC in 10mg lyophilised vials, independently HPLC-tested to ≥99.0% purity. For laboratory research use only.
Mechanism. GHRH receptor agonist — stimulates pituitary GH release through the GHRH pathway.
Half-life. ~30 minutes (pulsatile release) — vs 7–10 days for the DAC variant.
Research pairing. Most commonly studied with Ipamorelin (GHS-R agonist) for combined GHRH + GHRP axis research.
Research Background
The original CJC-1295 compound series was investigated by Ionescu and colleagues, with published work in the Journal of Clinical Endocrinology & Metabolism (2006;91:799–805) demonstrating dose-dependent GH and IGF-1 increases in healthy adult subjects. This work established the pharmacokinetic profile of the DAC variant and provided the basis for understanding how structural modifications to native GHRH affect receptor affinity and plasma stability.
The No DAC variant emerged from research interest in preserving pulsatile GH secretion patterns rather than producing the sustained GH elevation seen with the albumin-binding DAC modification. Pulsatile GH signalling is considered physiologically relevant in multiple research contexts, including IGF-1 axis studies, body composition research, and sleep-stage GH secretion modelling in animal experiments.
CJC-1295 No DAC is predominantly studied in combination with GHS-R agonists, particularly Ipamorelin, because the two peptides operate through mechanistically complementary pathways — GHRH signalling (CJC-1295) and ghrelin receptor signalling (Ipamorelin) — which have been shown to produce synergistic GH release in rodent pituitary research models.
Key citation Ionescu M & Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." J Clin Endocrinol Metab. 2006;91(12):4792–4797.
Compound Specifications
| Common Name |
CJC-1295 No DAC (Modified GRF 1-29) |
| Structure |
29 amino acids · 4 substituted residues |
| Molecular Weight |
3367.97 g/mol |
| Receptor Target |
GHRH receptor (pituitary) |
| Purity (HPLC) |
≥99.0% — independently verified |
| Vial Size |
10mg lyophilised powder |
| Storage |
2–8°C (short-term) · −20°C (long-term) |
| Primary Reference |
Ionescu M et al., JCEM 2006;91:799–805 |
Storage & Handling
- Unopened vial: 2–8°C for regular use; −20°C for storage beyond 3 months.
- Reconstituted: 2–8°C, use within 28 days. Avoid freeze-thaw cycles.
- Reconstitution: Sterile bacteriostatic water. Use our free reconstitution calculator.
See our Storage & Handling Guide and Reconstitution Lab Guide for complete protocols.
Ordering & Pricing — Australia
| Quantity |
Price per vial |
Saving |
| 1–4 vials |
$129.95 AUD |
— |
| 5–9 vials |
$119.95 AUD |
Save 8% |
| 10+ vials |
$109.95 AUD |
Save 15% |
Free priority tracked shipping on orders over $250 AUD. Dispatched within 24 hours. Wholesale enquiries welcome.
Frequently Asked Questions
What is CJC-1295 No DAC?
CJC-1295 No DAC is a modified GHRH analogue (based on GHRH 1-29) with four amino acid substitutions for DPP-IV resistance. It produces pulsatile GH release in research models, with a half-life of approximately 30 minutes. For laboratory research use only.
What is the difference between CJC-1295 with and without DAC?
The DAC (Drug Affinity Complex) modification enables covalent albumin binding for a 7–10 day half-life and sustained GH elevation. No DAC has ~30 minute half-life and produces pulsatile, physiologically-patterned GH release. Most research uses the No DAC variant.
Should CJC-1295 No DAC be used with Ipamorelin?
CJC-1295 No DAC and Ipamorelin are the most commonly co-studied GHRH/GHS-R research peptide combination. They operate through complementary GH-releasing pathways (GHRH and ghrelin receptor) with observed synergistic GH release in preclinical models.
Is CJC-1295 No DAC available in Australia?
ClaraScience stocks CJC-1295 No DAC in our Australian warehouse. Orders dispatch within 24 hours. For research use only.
What purity is your CJC-1295 No DAC?
≥99.0% HPLC-verified at a WHO/GMP-certified third-party laboratory. Full COA with HPLC chromatogram and mass spectrometry identity confirmation with every batch.
